Arbutus Biopharma Corp Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Arbutus Biopharma Corp stock issued during period, value, new issues for the quarter ending 2022-09-30 was $8.97M, a 79.94% decline year-over-year.
- Arbutus Biopharma Corp stock issued during period, value, new issues for the quarter ending 2021-09-30 was $44.74M, a 8.25% decline year-over-year.
- Arbutus Biopharma Corp stock issued during period, value, new issues for the quarter ending 2021-06-30 was $4.27M, a 15.28% decline year-over-year.
- Arbutus Biopharma Corp stock issued during period, value, new issues for the quarter ending 2021-03-31 was $26.42M, a 114.53% increase year-over-year.
- Arbutus Biopharma Corp stock issued during period, value, new issues for fiscal 2021 was $134.66M, a 56.05% increase from fiscal 2020.
- Arbutus Biopharma Corp stock issued during period, value, new issues for fiscal 2020 was $86.30M, a 363.94% increase from fiscal 2019.
- Arbutus Biopharma Corp stock issued during period, value, new issues for fiscal 2019 was $18.60M, a 71.93% decline from fiscal 2018.
- Arbutus Biopharma Corp stock issued during period, value, new issues for fiscal 2018 was $66.27M, a 35.60% increase from fiscal 2017.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2022-09-30 | $8.97M 10-Q · filed 2022-11-09 | |
| 2021-12-31 | $134.66M 10-K · filed 2022-03-03 | |
| 2021-09-30 | $44.74M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $4.27M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $26.42M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $86.30M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $48.76M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $5.04M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $12.31M 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $18.60M 10-K · filed 2021-03-04 | |
| 2019-06-30 | $2.48M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $2.25M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $66.27M 10-K · filed 2019-03-07 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-05 | |
| 2018-03-31 | $66.27M 10-Q · filed 2019-11-06 | |
| 2017-12-31 | $48.87M 10-K · filed 2019-03-07 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $142.18M 10-K · filed 2018-03-16 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $142.18M derived: sum of 4 quarters · filed 2017-03-22 |
| 2015-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $142.18M derived: sum of 4 quarters · filed 2017-03-22 |
| 2015-03-31 | $142.18M 10-Q · filed 2015-05-06 | $142.18M derived: sum of 4 quarters · filed 2017-03-22 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-22 | $56.48M 10-K · filed 2017-03-22 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | |
| 2014-03-31 | $56.48M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $32.04M 10-K · filed 2016-03-09 | |
| 2012-12-31 | 3.04M CAD 20-F · filed 2013-03-27 | |
| 2012-12-31 | $3.04M 10-K · filed 2015-03-13 | |
| 2011-12-31 | 3.88M CAD 20-F · filed 2013-03-27 | |
| 2011-12-31 | $3.93M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |